ClinicalTrials.gg
CompletedNCT01854697MALACHITE 1Updated Jun 6, 2018Results posted

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing paritaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. paritaprevir · Hepatitis C, Chronic.

Enrollment
5th of 16
311 · median 124
Started
2013
with 1 other
Phase 3
9 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
9 of 16
AbbVie

Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 5th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 16 studies testing paritaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

About paritaprevir

paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing paritaprevir in Hepatitis C, Chronic as a file.
02

Study summary

This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.

Read the detailed description

The primary purpose of this study is to demonstrate that treatment with ABT-450/ritonavir (r)/ABT-267 and ABT-333 administered with or without ribavirin (RBV) has non-inferior efficacy compared to treatment with telaprevir and pegylated interferon alpha-2a (pegIFN) and RBV and to compare the safety of these regimens in treatment-naive hepatitis C virus (HCV) genotype (GT) 1a- and 1b-infected adults.

03

Conditions studied

  • Chronic Hepatitis C Infection

Keywords

  • Chronic Hepatitis C
  • Interferon Free
  • Hepatitis C Treatment Naive
  • Hepatitis C Virus
  • Hepatitis C Genotype 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females between 18 and 65 years, inclusive, at time of Screening
  • Females must be for more than 2 years or surgically sterile or practicing abstinence/specific forms of
  • Subject has never received antiviral treatment for infection
  • Chronic HCV Genotype-1 infection prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  • Positive test result for surface antigen (HBsAg) or anti- antibody (HIV Ab)
  • Females who are pregnant or plan to become pregnant, or breastfeeding
  • Any current or past clinical evidence of cirrhosis
  • Screening laboratory analyses that showing abnormal laboratory results
  • Use of medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV
  • Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol
  • Positive screen for drugs or alcohol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Arm A: 3-DAA + RBV in GT1a

    ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals \[DAAs\] with RBV in GT1a)

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin

  • Active comparator
    Arm B: TPV/PR in GT1a

    Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)

    Drug: Ribavirin · Drug: Telaprevir · Drug: Pegylated Interferon alpha 2-a (PegIFN)

  • Experimental
    Arm C: 3-DAA + RBV in GT1b

    ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin

  • Experimental
    Arm D: 3-DAA in GT1b

    ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)

    Drug: ABT-450/r/ABT-267, ABT-333

  • Active comparator
    Arm E: TPV/PR in GT1b

    Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)

    Drug: Ribavirin · Drug: Telaprevir · Drug: Pegylated Interferon alpha 2-a (PegIFN)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of active study drug

Secondary outcomes

  1. Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)

    SF-36V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQoL) covering 2 summary measures: physical component summary (PCS) and MCS; it consists of 8 subscales. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Scoring is done for both MCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).

    Time frame: From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E

  2. Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)

    SF-36V2 is a generic 36-item questionnaire measuring HRQoL covering 2 summary measures: PCS and MCS; it consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).

    Time frame: From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E

  3. Percentage of Participants With SVR12 - Secondary Efficacy Analyses

    The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of active study drug

  4. Percentage of Participants With Virologic Failure During Treatment

    Participants in Arms A, C or D demonstrating any of the following were considered virologic failures and discontinued therapy: * Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of \>1 log10 IU/mL above nadir) at any time point during treatment * Failure to achieve HCV RNA \< LLOQ by Week 6 or * Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point after HCV RNA \< LLOQ during treatment after HCV RNA \< LLOQ. Participants in Arms B and E followed virologic stopping criteria described in the TPV Summary of Product Characteristics; they were considered virologic failures and discontinued therapy as follows: * HCV RNA \> 1000 IU/mL at Week 4 to Week 12, discontinue TPV and pegIFN and RBV * HCV RNA \> 1000 IU/mL at Week 12, discontinue pegIFN and RBV * Confirmed HCV RNA \> lower limit of detection (LLOD) at Week 24, discontinue pegIFN and RBV * Confirmed HCV RNA \> LLOD at Week 36, discontinue pegIFN and RBV.

    Time frame: 12 weeks for Arms A, C and D and 24 weeks or 48 weeks for Arms B and E

  5. Percentage of Participants With Post-treatment Relapse

    Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 24 weeks post treatment among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment.

    Time frame: Within 24 weeks post treatment

  6. Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)

    The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 24 weeks after the last dose of study drug.

    Time frame: 24 weeks after the last actual dose of active study drug

07

Results

Posted Feb 22, 2016

Participant flow

Participant flow — Overall Study
MilestoneArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Started6934848341
Completed6331828039
Not completed63232
Withdrew: Adverse event10001
Withdrew: Lost to follow-up41120
Withdrew: To enter another abbvie study10001
Withdrew: Withdrew consent01010
Withdrew: Other01100

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses
percentage of participantsArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses97.182.498.897.678.0
Statistical analysis
  • Arm A: 3-DAA + RBV in GT1a vs Arm B: TPV/PR in GT1a · Difference: 14.7 · 95% CI 1.3 to 28.2Difference (95% CI) from TPV/PR within GT1a. Calculated using the normal approximation to the binomial distribution.
  • Arm D: 3-DAA in GT1b vs Arm E: TPV/PR in GT1b · Difference: 19.5 · 95% CI 6.4 to 32.6Difference (95% CI) from TPV/PR within GT1b. Calculated using the normal approximation to the binomial distribution.
SecondaryMean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)

SF-36V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQoL) covering 2 summary measures: physical component summary (PCS) and MCS; it consists of 8 subscales. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Scoring is done for both MCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).

Time frame:
From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E
Reported as:
Mean · units on a scale
Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)
units on a scaleArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)-4.2 ± 10.59-5.8 ± 12.18-0.3 ± 8.89-0.1 ± 7.73-6.4 ± 11.78
Statistical analysis
  • Arm A: 3-DAA + RBV in GT1a vs Arm B: TPV/PR in GT1a · ANCOVA · p = 0.351 · Least squares mean difference: 2.13 · 95% CI -2.39 to 6.65ANCOVA model included baseline score and region as covariates and treatment arm as a factor.
  • Arm C: 3-DAA + RBV in GT1b vs Arm E: TPV/PR in GT1b · ANCOVA · p = 0.002 · Least squares mean of difference: 5.83 · 95% CI 2.19 to 9.47ANCOVA model included baseline score and region as covariates and treatment arm as a factor.
  • Arm D: 3-DAA in GT1b vs Arm E: TPV/PR in GT1b · ANCOVA · p = 0.002 · Least squares mean of difference: 5.28 · 95% CI 2.01 to 8.54ANCOVA model included baseline score and region as covariates and treatment arm as a factor.
SecondaryMean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)

SF-36V2 is a generic 36-item questionnaire measuring HRQoL covering 2 summary measures: PCS and MCS; it consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).

Time frame:
From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E
Reported as:
Mean · units on a scale
Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)
units on a scaleArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)0.5 ± 8.63-5.5 ± 8.260.4 ± 5.802.2 ± 4.34-5.5 ± 11.46
Statistical analysis
  • Arm A: 3-DAA + RBV in GT1a vs Arm B: TPV/PR in GT1a · ANCOVA · p = <0.001 · Least squares mean difference: 6.08 · 95% CI 2.72 to 9.44ANCOVA model included baseline score and region as covariates and treatment arm as a factor.
  • Arm C: 3-DAA + RBV in GT1b vs Arm E: TPV/PR in GT1b · ANCOVA · p = <0.001 · Least squares mean difference: 6.20 · 95% CI 3.55 to 8.85ANCOVA model included baseline score and region as covariates and treatment arm as a factor.
  • Arm D: 3-DAA in GT1b vs Arm E: TPV/PR in GT1b · ANCOVA · p = <0.001 · Least squares mean difference: 6.86 · 95% CI 4.36 to 9.37ANCOVA model included baseline score and region as covariates and treatment arm as a factor.
SecondaryPercentage of Participants With SVR12 - Secondary Efficacy Analyses

The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Participants With SVR12 - Secondary Efficacy Analyses
percentage of participantsArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Percentage of Participants With SVR12 - Secondary Efficacy Analyses97.182.498.897.678.0
Statistical analysis
  • Arm A: 3-DAA + RBV in GT1a vs Arm B: TPV/PR in GT1a · Regression, Logistic · p = 0.021 · Odds ratio (or): 7.2 · 95% CI 1.4 to 38.0Logistic regression model with treatment arm, baseline log10 HCV RNA level, and interleukin 28B (IL28B) genotype (CC versus non-CC) as predictors.
  • Arm C: 3-DAA + RBV in GT1b vs Arm E: TPV/PR in GT1b · Difference: 20.8 · 95% CI 7.9 to 33.6Difference (95% CI) from TPV/PR within GT1b. Calculated using the normal approximation to the binomial distribution.
  • Arm C: 3-DAA + RBV in GT1b vs Arm E: TPV/PR in GT1b · Regression, Logistic · p = 0.002 · Odds ratio (or): 28.2 · 95% CI 3.3 to 241.1Calculated using logistic regression model with treatment arm, baseline log10 HCV RNA level, and IL28B genotype (CC versus non-CC) as predictors.
  • Arm D: 3-DAA in GT1b vs Arm E: TPV/PR in GT1b · Cochran-Mantel-Haenszel · p = 0.005Stratum-adjusted Cochran-Mantel-Haenszel after adjusting for IL28B genotype (CC or non-CC).
SecondaryPercentage of Participants With Virologic Failure During Treatment

Participants in Arms A, C or D demonstrating any of the following were considered virologic failures and discontinued therapy: * Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of \>1 log10 IU/mL above nadir) at any time point during treatment * Failure to achieve HCV RNA \< LLOQ by Week 6 or * Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point after HCV RNA \< LLOQ during treatment after HCV RNA \< LLOQ. Participants in Arms B and E followed virologic stopping criteria described in the TPV Summary of Product Characteristics; they were considered virologic failures and discontinued therapy as follows: * HCV RNA \> 1000 IU/mL at Week 4 to Week 12, discontinue TPV and pegIFN and RBV * HCV RNA \> 1000 IU/mL at Week 12, discontinue pegIFN and RBV * Confirmed HCV RNA \> lower limit of detection (LLOD) at Week 24, discontinue pegIFN and RBV * Confirmed HCV RNA \> LLOD at Week 36, discontinue pegIFN and RBV.

Time frame:
12 weeks for Arms A, C and D and 24 weeks or 48 weeks for Arms B and E
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure During Treatment
percentage of participantsArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Percentage of Participants With Virologic Failure During Treatment2.95.901.212.2
SecondaryPercentage of Participants With Post-treatment Relapse

Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 24 weeks post treatment among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment.

Time frame:
Within 24 weeks post treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participantsArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Percentage of Participants With Post-treatment Relapse001.206.3
SecondaryPercentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)

The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 24 weeks after the last dose of study drug.

Time frame:
24 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)
percentage of participantsArm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1b
Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)95.782.497.697.678.0
Statistical analysis
  • Arm A: 3-DAA + RBV in GT1a vs Arm B: TPV/PR in GT1a · Difference: 13.3 · 95% CI -0.4 to 27.0Difference (95% CI) from TPV/PR within GT1a. Calculated using the normal approximation to the binomial distribution.
  • Arm C: 3-DAA + RBV in GT1b vs Arm E: TPV/PR in GT1b · Difference: 19.6 · 95% CI 6.5 to 32.7Difference (95% CI) from TPV/PR within GT1b. Calculated using the normal approximation to the binomial distribution.
  • Arm D: 3-DAA in GT1b vs Arm E: TPV/PR in GT1b · Difference: 19.5 · 95% CI 6.4 to 32.6Difference (95% CI) from TPV/PR within GT1b. Calculated using the normal approximation to the binomial distribution.

Adverse events

Collected over Adverse Events (AEs) collected from time of study drug administration until 30 days following discontinuation or completion of study drug administration, up to 96 weeks. Serious AEs collected from signing of informed consent until study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 DAA + RBV—1/153 (0.7%)100/153 (65.4%)
3 DAA—0/83 (0%)29/83 (34.9%)
TPV + PEGIFN + RBV—9/75 (12%)74/75 (98.7%)
Most frequent serious events
Most frequent serious events
Event3 DAA + RBV3 DAATPV + PEGIFN + RBV
ANAEMIABlood and lymphatic system disorders0/1530/832/75
RETINOPATHYEye disorders0/1530/831/75
HAEMATOCHEZIAGastrointestinal disorders0/1530/831/75
CHEST PAINGeneral disorders0/1530/831/75
ABSCESS LIMBInfections and infestations0/1530/831/75
CELLULITISInfections and infestations0/1530/831/75
ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications0/1530/831/75
COUGHRespiratory, thoracic and mediastinal disorders0/1530/831/75
TOXIC SKIN ERUPTIONSkin and subcutaneous tissue disorders0/1530/831/75
PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1530/830/75
Most frequent other events
Showing 10 of 44
Most frequent other events
Event3 DAA + RBV3 DAATPV + PEGIFN + RBV
ANAEMIABlood and lymphatic system disorders10/1531/8332/75
NAUSEAGastrointestinal disorders32/1537/8330/75
PRURITUSSkin and subcutaneous tissue disorders19/1535/8326/75
FATIGUEGeneral disorders21/1534/8323/75
HEADACHENervous system disorders41/15316/8323/75
DECREASED APPETITEMetabolism and nutrition disorders6/1531/8317/75
RASHSkin and subcutaneous tissue disorders12/1530/8317/75
PYREXIAGeneral disorders4/1532/8316/75
ASTHENIAGeneral disorders11/1532/8315/75
NEUTROPENIABlood and lymphatic system disorders0/1530/8314/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1bTotal
Mean46.1 ± 12.2544.5 ± 14.1046.2 ± 11.3447.1 ± 11.3345.9 ± 10.7846.2 ± 11.75
Age, Customized
Age, Customized(participants)Arm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1bTotal
< 55 years4623596031219
>= 55 years231125231092
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: 3-DAA + RBV in GT1aArm B: TPV/PR in GT1aArm C: 3-DAA + RBV in GT1bArm D: 3-DAA in GT1bArm E: TPV/PR in GT1bTotal
Female2117464324151
Male4817384017160
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, Ghesquiere W, Mazur W, Soza A, Fuster F, Greenbloom S, Motoc A, Arama V, Shaw D, Tornai I, Sasadeusz J, Dalgard O, Sullivan D, Liu X, Kapoor M, Campbell A, Podsadecki T. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. J Hepatol. 2016 Jan;64(1):19-28. doi: 10.1016/j.jhep.2015.08.015. Epub 2015 Aug 29. PubMed 26321288 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Nov 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2013
First posted
May 15, 2013
Start
Mar 2013
Primary completionActual
Nov 2014
CompletionActual
Jul 2015
Results first posted
Feb 22, 2016
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01854697
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 15, 2013
Start date
Mar 2013
Primary completion
Nov 2014
Completion
Jul 2015
Results posted
Feb 22, 2016
Last update
Jun 6, 2018

Study contacts

Yan Luo, MD, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir · Ribavirin

Start the discussion